StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Amit Seth

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byAmit SethHorizon: NA (inferred Intraday)7 Jul 2026, 12:49 pm ISTvia CNBC Awaaz.

Entry₹2,286Inferred
Target₹2,350
Total upside +2.80% (call closed)
Stop loss₹2,250-1.57% risk
Exit₹2,2507 Jul 2026, 1:12 pm
Stop-loss hit-1.57%
Follow Amit Seth for new calls(4% target hit, 81 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:48 pm IST
3 supporting0 opposing
Supports the BUY call (3)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·7 Jul · today

Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial.

NSE · Press Release·6 Jul · yesterday

(opens in new tab)

Glenmark Pharmaceuticals Ltd is advancing its Multi-Country Phase 3 Clinical Trial of Trastuzmab rezetecan in Platinum-Resistant Ovarian Cancer.

BSE · Company Update·2 Jul · 5d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Amit Seth

Every call and its outcome